Veracyte Continues Cancer IVD Expansion By Acquiring HalioDx For $318M
The deal is Veracyte’s second major acquisition in cancer diagnostics in 2021 after agreeing to acquire Decipher Biosciences in March.
You may also be interested in...
Deal-making and financing activities are on the rise for liquid biopsy diagnostic products in 2021 despite questions remaining around whether the technology can unseat standard-of-care biomarker and imaging tests.
Inivata will remain a separate liquid biopsy division alongside NeoGenomics’ growing clinical, pharma and informatics divisions.
With the addition of Decipher, Veracyte now offers tests for seven of the 10 most common types of cancer in the US.